1137142-58-5

Basic information

• Product Name: 2-Bromoimidazo[2,1-b][1,3,4]thiadiazole
• Synonyms: 2-Bromoimidazo[2,1-b][1,3,4]thiadiazole
• CAS NO: 1137142-58-5
• Molecular Formula: C₄H₂BrN₃S
• Molecular Weight: 204.04778
• Mol File: 1137142-58-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 2.34±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.74±0.50(Predicted)
• CAS DataBase Reference: 2-Bromoimidazo[2,1-b][1,3,4]thiadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromoimidazo[2,1-b][1,3,4]thiadiazole(1137142-58-5)
• EPA Substance Registry System: 2-Bromoimidazo[2,1-b][1,3,4]thiadiazole(1137142-58-5)

Safety Data

• Hazardous Substances Data: 1137142-58-5(Hazardous Substances Data)

Usage

Description

2-Bromoimidazo[2,1-b][1,3,4]thiadiazole is a heterocyclic compound characterized by the presence of a bromine atom and an imidazole ring fused to a thiadiazole ring. This unique structure endows it with a wide range of biological activities and potential therapeutic applications, making it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and functional materials.

Uses

Used in Pharmaceutical Industry:
2-Bromoimidazo[2,1-b][1,3,4]thiadiazole is used as a building block for the synthesis of various pharmaceutical compounds due to its diverse biological activities. Its anti-cancer properties make it a promising candidate for the development of novel cancer therapeutics. Additionally, its antimicrobial and antiviral properties contribute to the creation of new treatments for infectious diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Bromoimidazo[2,1-b][1,3,4]thiadiazole serves as a key intermediate in the synthesis of agrochemicals with pesticidal and herbicidal properties. Its unique structure and reactivity allow for the development of effective and targeted agrochemical products.
Used in Materials Science:
2-Bromoimidazo[2,1-b][1,3,4]thiadiazole is utilized in materials science for the synthesis of functional materials and polymer additives. Its unique chemical properties enable the creation of innovative materials with specific characteristics, such as improved stability, enhanced reactivity, or tailored electronic properties, which can be applied in various industries, including electronics, coatings, and adhesives.

Upstream product

• 107-20-0 2-chloroethanal 
• 37566-39-5 5-bromo-2-amino-1,3,4-thiadiazole 

Downstream Products

• 1137143-05-5 imidazo[2,1-b][1,3,4]thiadiazol-2-yl-(4-methoxyphenyl)amine 
• 1137142-95-0 2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazole 
• 1137143-01-1 (4-fluorophenyl)-(imidazo[2,1-b][1 ,3,4]thiadiazol-2-yl)amine 

Relevant articles and documents

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES

There is provided compounds of formula (I): wherein R1, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K) is desired and/or required, and particularly in the treatment of cancer.

IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS

There is provided compounds of formula (I), wherein Z, M, R1, X, R2, R3 and B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PIM family kinase or PI3-K) is desired and/or required, and particularly in the treatment of cancer.